Apogee Therapeutics secures $1.3B non-dilutive financing from Blackstone Life Sciences

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences providing up to $1.3 billion in non-dilutive capital, including $800 million in synthetic royalty and $500 million in senior debt, to fund Phase 3 development and commercialization of zumilokibart for atopic dermatitis. Combined with existing cash reserves of $1.3 billion, this positions the company to reach profitability without future equity dilution.